Phase 1 BPL-003 Studies in Healthy Volunteers
We are conducting a Phase 1 study of BPL-003 in healthy volunteers in London. This is a two-part, double-blind, placebo-controlled, randomised, single ascending dose study to evaluate the safety, tolerability and the pharmacokinetic and pharmacodynamic profile of intranasal BPL-003 (5-Methoxy-N,N-dimethyltryptamine Benzoate) in healthy subjects.
Phase 1 ELE -101 Studies in Healthy Volunteers
We are conducting a Phase 1 study of ELE -101 in healthy volunteers in Manchester and Liverpool. This is a Phase I, double-blind, placebo-controlled, randomised single ascending dose study to assess the safety, tolerability, pharmacokinetic (PK) profile, pharmacodynamic (PD) and subjective drug intensity (SDI) of intravenous (IV) doses of ELE-101 in healthy male and female adult participants.
Investigator Initiated Studies
We are committed to understanding the therapeutic potential of psychedelic drugs and support rigorous investigator-initiated research advancing psychedelic science.
We work in collaboration with select academic institutions and researchers.